Fig. 5: Reproducibility of the REMIT assay for paclitaxel and eribulin sensitivity assessment. | npj Breast Cancer

Fig. 5: Reproducibility of the REMIT assay for paclitaxel and eribulin sensitivity assessment.

From: Development and validation of a functional ex vivo paclitaxel and eribulin sensitivity assay for breast cancer, the REMIT assay

Fig. 5: Reproducibility of the REMIT assay for paclitaxel and eribulin sensitivity assessment.

All replicates from the tested PDX models plotted and scored separately for paclitaxel (a) and eribulin (b) sensitivity. Thresholds applied in the graphs are the same as depicted in Figs. 2 and 4, respectively. Blue lines represent replicates scored as resistant to paclitaxel and pink as sensitive to paclitaxel treatment. c Schematic overview of the scoring performed for each of the PDX replicates separately with the division between the models. Calculations represent the reproducibility of the assay for each models separately and an average value for paclitaxel and eribulin assay. For paclitaxel, the reproducibility based on the correlation between in vivo and ex vivo sensitivity was also calculated. Numbers within the colored squares represent the PDX replicate included in the analysis.

Back to article page